Decentralized Clinical Trials Market Report 2025

The decentralized clinical trials market size has grown rapidly in recent years. It will grow from $7.44 billion in 2024 to $8.77 billion in 2025 at a compound annual growth rate (CAGR) of 17.8%. Growth in the historic period was driven by the rising adoption of electronic data capture systems, increasing use of wearable health monitoring devices, growing regulatory support for patient-centric trials, higher demand for cost-efficient trial models, and expansion of remote monitoring technologies.

The decentralized clinical trials market size is expected to see rapid growth in the next few years. It will grow to $16.68 billion in 2029 at a compound annual growth rate (CAGR) of 17.5%. Growth in the forecast period is expected to be supported by the integration of artificial intelligence and machine learning in clinical trials, greater adoption of blockchain for data security, rising prevalence of rare and chronic diseases promoting decentralized trial models, increased use of real-world evidence in trial design, and expansion of 5G connectivity enabling seamless trial operations. Key trends anticipated for the forecast period include the integration of AI and machine learning, adoption of wearable and biosensor technologies, increased use of telemedicine and remote monitoring, blockchain-enabled data security and transparency, and growth of cloud-based clinical trial management platforms.

The increasing emphasis on telemedicine is expected to support the growth of the decentralized clinical trials market in the years ahead. Telemedicine refers to the remote delivery of healthcare services through digital communication tools, allowing patients to receive consultations and monitoring without visiting healthcare facilities in person. This shift toward telemedicine is largely driven by the demand for accessible healthcare in response to global health challenges and social distancing measures. Decentralized clinical trials leverage telemedicine to remotely engage participants and monitor their progress, reducing the need for physical site visits while enabling real-time data collection, broader participation, and continuous oversight. For example, in August 2023, Vivalink, a healthcare technology company based in the United States, reported that eighty-one percent of clinicians were using remote patient monitoring, a significant increase from twenty percent in 2021. In addition, eighty-four percent of those currently using remote patient monitoring intended to expand their use in 2024. As a result, the growing focus on telemedicine is contributing to the expansion of the decentralized clinical trials market.

Companies operating in the decentralized clinical trials market are advancing their offerings by developing all-in-one, no-code clinical trial software solutions that simplify trial setup and improve efficiency and patient engagement. These platforms enable researchers to create and manage trials without writing code, while incorporating essential functions such as patient recruitment, data collection, monitoring, and analytics into one user-friendly system. For example, in August 2024, Medable, a clinical technology company based in the United States, introduced Medable Studio, an all-in-one, no-code software platform designed to streamline the configuration, translation, validation, and launch of electronic Clinical Outcome Assessments, electronic consent, remote consultations, and sensor integrations in clinical trials. This tool allows biopharmaceutical companies to develop protocol-specific study designs in a matter of hours rather than months, offering increased control, speed, and transparency. Users can choose from self-service, full-service, or hybrid options, which significantly shorten study startup timelines and reduce costs. The platform aims to transform trial execution by making the study setup process faster and less reliant on external services.

In July 2023, Signant Health, a United States-based provider of evidence generation solutions for modern clinical trials, completed the acquisition of DSG Incorporated for an undisclosed sum. This acquisition is intended to expand Signant Health’s suite of electronic clinical solutions by incorporating DSG’s unified electronic data capture and direct data capture platform. The integration of these technologies offers flexible and comprehensive support for both traditional and decentralized clinical trials. This move enhances operational efficiency, simplifies trial workflows, and improves digital tools available to sponsors, research sites, and clinical research organizations. DSG Incorporated is a United States-based company that provides electronic data capture and direct data capture technology within a unified clinical platform for use in site-based and decentralized clinical trials.

Major players in the decentralized clinical trials market are Walgreens Boots Alliance Inc., Pfizer Inc., Oracle Corporation, Thermo Fisher Scientific Inc., IQVIA Holdings Inc., Labcorp Holdings Inc., ICON Public Limited Company, Dassault Systèmes SE, LEO Pharma A/S, Verily Life Sciences LLC, ProPharma, Signant Health Holding Corp., PCM Trials, Huma Therapeutics Limited, Medable Inc., Science 37 Inc., Obvio Health, EmVenio Research Inc., Grove AI Inc., Phesi Inc.

North America was the largest region in the decentralized clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in decentralized clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the decentralized clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Decentralized clinical trials are an innovative approach to conducting clinical research that utilizes digital tools and remote processes to engage participants outside traditional trial sites. They streamline data collection and monitoring in real time, improving trial efficiency. Decentralized clinical trials also enhance accessibility, allowing broader and more diverse participation, and accelerate research timelines while reducing operational challenges.

The primary types of decentralized clinical trials are interventional, observational, and expanded access. Interventional trials involve assigning participants to specific interventions to assess their effects on health outcomes. Key technologies include wearable devices, mobile health applications, telemedicine platforms, and electronic data capture systems. These trials span study phases from phase I through phase IV and are applied across therapeutic areas such as oncology, cardiology, neurology, and infectious diseases. End-users include pharmaceutical companies, biotechnology firms, contract research organizations, regulatory authorities, and academic and research institutions.

The decentralized clinical trials market research report is one of a series of new reports that provides decentralized clinical trials market statistics, including decentralized clinical trials industry global market size, regional shares, competitors with a decentralized clinical trials market share, detailed decentralized clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the decentralized clinical trials industry. The decentralized clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The decentralized clinical trials market consists of revenues earned by entities by providing services such as patient recruitment and retention, site management and monitoring, data management and analytics, regulatory compliance support, and telemedicine or virtual care solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The decentralized clinical trials market also includes sales of wearable health monitoring devices, electronic data capture systems, biosensors, remote patient monitoring equipment, and clinical trial management software. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities, wholesalers, distributors, and retailers or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.